相关论文: Automated Scoring System of HER2 in Pathological I…
The overexpression of human epidermal growth factor receptor 2 (HER2) has been established as a therapeutic target in multiple types of cancers, such as breast and gastric cancers. Immunohistochemistry (IHC) is employed as a basic HER2 test…
Breast cancer (BC) is the most common cancer among women world-wide, approximately 20-25% of BCs are HER-2 positive. Analysis of HER-2 is fundamental to defining the appropriate therapy for patients with breast cancer. Inter-pathologist…
Evaluating expression of the Human epidermal growth factor receptor 2 (Her2) by visual examination of immunohistochemistry (IHC) on invasive breast cancer (BCa) is a key part of the diagnostic assessment of BCa due to its recognised…
Human epidermal growth factor receptor 2 (HER2) is a critical protein in cancer cell growth that signifies the aggressiveness of breast cancer (BC) and helps predict its prognosis. Accurate assessment of immunohistochemically (IHC) stained…
The evaluation of the Human Epidermal growth factor Receptor-2 (HER2) expression is an important prognostic biomarker for breast cancer treatment selection. However, HER2 scoring has notoriously high interobserver variability due to stain…
Accurate assessment of human epidermal growth factor receptor 2 (HER2) expression is critical for breast cancer diagnosis, prognosis, and therapy selection; yet, most existing digital HER2 scoring methods rely on bulky and expensive optical…
Immunohistochemistry (IHC) analysis is a well-accepted and widely used method for molecular subtyping, a procedure for prognosis and targeted therapy of breast carcinoma, the most common type of tumor affecting women. There are four…
Breast cancer, the most common malignancy among women, requires precise detection and classification for effective treatment. Immunohistochemistry (IHC) biomarkers like HER2, ER, and PR are critical for identifying breast cancer subtypes.…
Breast cancer is one of the most common cancer in women around the world. For diagnosis, pathologists evaluate biomarkers such as HER2 protein using immunohistochemistry over tissue extracted by a biopsy. Through microscopic inspection,…
Estimating over-amplification of human epidermal growth factor receptor 2 (HER2) on invasive breast cancer (BC) is regarded as a significant predictive and prognostic marker. We propose a novel deep reinforcement learning (DRL) based model…
The popular use of histopathology images, such as hematoxylin and eosin (H&E), has proven to be useful in detecting tumors. However, moving such cancer cases forward for treatment requires accurate on the amount of the human epidermal…
Breast cancer is the most common malignancy in women, being responsible for more than half a million deaths every year. As such, early and accurate diagnosis is of paramount importance. Human expertise is required to diagnose and correctly…
Breast cancer is the most common cancer among women worldwide. Early-stage diagnosis of breast cancer can significantly improve the efficiency of treatment. Computer-aided diagnosis (CAD) systems are widely adopted in this issue due to…
Histo-pathological diagnostics are an inherent part of the everyday work but are particularly laborious and associated with time-consuming manual analysis of image data. In order to cope with the increasing diagnostic case numbers due to…
We developed a rapid scanning optical microscope, termed "BlurryScope", that leverages continuous image acquisition and deep learning to provide a cost-effective and compact solution for automated inspection and analysis of tissue sections.…
Human epidermal growth factor receptor 2 (HER2) is an important prognostic and predictive factor which is overexpressed in 15-20% of breast cancer (BCa). The determination of its status is a key clinical decision making step for selection…
The immunohistochemical (IHC) staining of the human epidermal growth factor receptor 2 (HER2) biomarker is widely practiced in breast tissue analysis, preclinical studies and diagnostic decisions, guiding cancer treatment and investigation…
The overexpression of the human epidermal growth factor receptor 2 (HER2) in breast cells is a key driver of HER2-positive breast cancer, a highly aggressive subtype requiring precise diagnosis and targeted therapy. Immunohistochemistry…
Generally, human epidermal growth factor 2 (HER2) breast cancer is more aggressive than other kinds of breast cancer. Currently, HER2 breast cancer is detected using expensive medical tests are most expensive. Therefore, the aim of this…
The current standard for detecting human epidermal growth factor receptor 2 (HER2) status in breast cancer patients relies on HER2 amplification, identified through fluorescence in situ hybridization (FISH) or immunohistochemistry (IHC).…